Indiana University Simon Cancer Center re-designated as NCI cancer center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center was recognized by NCI as a designated cancer center, and had their support grant increased by 20 percent, following an in-depth peer review.

NCI rated the cancer center’s research activities as “excellent,” and awarded it a five-year, $7.8 million support grant. The NCI designation places the IU Simon Cancer Center in a group of 68 cancer centers. It is the only NCI-designated cancer center in Indiana that provides patient care. The center first received the NCI designation in 1999, seven years after its founding.

“We are especially honored to be renewed with this very prized designation again,” said Patrick Loehrer, director of the IU Simon Cancer Center. “To receive a funding increase in the current funding climate is icing on the cake.”

Reviewers, composed of NCI officials and others from NCI-designated cancer centers, evaluated the cancer center’s five research programs and visited in February 2014. Members of those research programs are on the Indiana University-Purdue University Indianapolis, IU Bloomington, IU South Bend and Notre Dame campuses.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login